Lee’s Pharm In-licenses China Rights to Orphan Drug from Abiogen

Lee's Pharm of Hong Kong has in-licensed China distribution rights for Attila®, an orphan drug made by Abiogen, a privately held Italian pharma. Attila is indicated for Osteogenesis Imperfecta (OI), also known as brittle bone disease, and Complex Regional Pain Syndrome (CRPS), a neurologic disorder. Lee’s will be responsible for obtaining CFDA approval of the drug. More details.... Stock Symbol: (HK: 950) Share this with colleagues: // //